 |
 |
|
Home |
Current Issue |
Past Issues |
In the Clinic |
ACP Journal Club |
CME |
Collections |
Audio/Video |
Mobile |
Subscribe |
Tools |
Help |
ACP Online
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 May 1997 | Volume 126 Issue 9 | Pages 689-696
Background: Candidiasis is a frequent complication of infection with the human immunodeficiency virus (HIV); however, few data exist about the natural history, prevention, and treatment of mucosal candidiasis in women.
Objective: To evaluate the safety and effectiveness of weekly fluconazole prophylaxis for mucosal candidiasis in women infected with HIV.
Design: Randomized, double-blind, placebo-controlled trial.
Setting: 14 sites participating in the Community Programs for Clinical Research on AIDS (CPCRA).
Patients: 323 women with HIV infection and CD4+ cell counts of 300 cells/mm3 or less.
Intervention: 200 mg of fluconazole per week or placebo. Open-label fluconazole for candidiasis prophylaxis was permitted after two oropharyngeal or vaginal episodes or one esophageal episode.
Measurements: Development of mucosal candidiasis, clinical and in vitro resistance of Candida species to fluconazole, survival, and adverse events.
Results: After a median follow-up of 29 months, 72 of 162 patients receiving fluconazole and 93 of 161 patients receiving placebo had at least one episode of candidiasis (relative risk [RR], 0.56 [95% CI, 0.41 to 0.77]; P < 0.001). Weekly fluconazole was effective in preventing oropharyngeal candidiasis (RR, 0.50 [CI, 0.33 to 0.74]; P < 0.001) and vaginal candidiasis (RR, 0.64 [CI, 0.40 to 1.00]; P = 0.05) but not esophageal candidiasis (RR, 0.91 [CI, 0.48 to 1.72]; P > 0.2). Relative risks were similar for women who had a history of mucosal candidiasis (RR, 0.51 [CI, 0.35 to 0.75]) and those who did not (RR, 0.69 [CI, 0.35 to 1.34]). Absolute risk reduction for patients with a history of infection was 25.6 per 100 person-years, which is more than twice the reduction of 11.2 per 100 person-years seen in patients with no history of infection. This difference reflects the higher risk of patients who previously had an infection. Candida albicans was not usually resistant to fluconazole in vaginal specimens in clinical or in vitro settings; such resistance occurred in less than 5% of patients in each group.
Conclusions: Weekly fluconazole (200 mg) seems to be safe and effective in preventing oropharyngeal and vaginal candidiasis. This regimen has a useful role in the management of HIV-infected women who are at risk for recurrent mucosal candidiasis.
Author and Article Information
The Terry Beirn Community Programs for Clinical Research on AIDS.
ARTICLE
Weekly Fluconazole for the Prevention of Mucosal Candidiasis in Women with HIV Infection
A Randomized, Double-Blind, Placebo-Controlled Trial
Acknowledgments: The authors thank Barbara Brizz, Carroll Child, Marjorie Dehlinger, Lawrence Deyton, Kathy Canady, Perry Eisman, Betsy Finley, and Dianne Murphy; the former DAIDS Medical Officer, Joyce Korvick; and the laboratory technologist, Kathleen M. Furness.
Requests for Reprints: Paula Schuman, MD, MPH, Division of Infectious Diseases, Wayne State University, Harper Professional Building, 4160 John R Road, Suite 2140, Detroit, MI 48201.
Current Author Addresses: Drs. Schuman, Vazquez, and Sobel: Division of Infectious Diseases, Wayne State University, Harper Professional Building, 4160 John R Road, Suite 2140, Detroit, MI 48201.
This article has been cited by other articles:
|
|
 |
|
  C. Charlier, E. Hart, A. Lefort, P. Ribaud, F. Dromer, D. W. Denning, and O. Lortholary Fluconazole for the management of invasive candidiasis: where do we stand after 15 years? J. Antimicrob. Chemother., March 1, 2006; 57(3): 384 - 410. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. L. Duffalo Fungal Opportunistic Infections in HIV Disease Journal of Pharmacy Practice, February 1, 2006; 19(1): 17 - 30. [Abstract] [PDF]
|
|
|
|
 |
|
 J. D. Sobel, H. C. Wiesenfeld, M. Martens, P. Danna, T. M. Hooton, A. Rompalo, M. Sperling, C. Livengood III, B. Horowitz, J. Von Thron, et al. Maintenance Fluconazole Therapy for Recurrent Vulvovaginal Candidiasis N. Engl. J. Med., August 26, 2004; 351(9): 876 - 883. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. D. Sobel, M. Zervos, B. D. Reed, T. Hooton, D. Soper, P. Nyirjesy, M. W. Heine, J. Willems, and H. Panzer Fluconazole Susceptibility of Vaginal Isolates Obtained from Women with Complicated Candida Vaginitis: Clinical Implications Antimicrob. Agents Chemother., January 1, 2003; 47(1): 34 - 38. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. b. H. Masur, J. E. Kaplan, and K. K. Holmes Guidelines for Preventing Opportunistic Infections among HIV-Infected Persons--2002: Recommendations of the U.S. Public Health Service and the Infectious Diseases Society of America Ann Intern Med, September 3, 2002; 137(5_Part_2): 435 - 478. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-L. Pagani, J.-P. Chave, C. Casjka, M.-P. Glauser, and J. Bille Efficacy, tolerability and development of resistance in HIV-positive patients treated with fluconazole for secondary prevention of oropharyngeal candidiasis: a randomized, double-blind, placebo-controlled trial J. Antimicrob. Chemother., August 1, 2002; 50(2): 231 - 240. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A Akpan and R Morgan Oral candidiasis Postgrad. Med. J., August 1, 2002; 78(922): 455 - 459. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Kovacs and H. Masur Prophylaxis against Opportunistic Infections in Patients with Human Immunodeficiency Virus Infection N. Engl. J. Med., May 11, 2000; 342(19): 1416 - 1429. [Full Text] [PDF]
|
|
|
|
|
|
USPHS/IDSA Prevention of Opportunistic Infections 1999 USPHS/IDSA Guidelines for the Prevention of Opportunistic Infections in Persons Infected with Human Immunodeficiency Virus Ann Intern Med, December 7, 1999; 131(11): 873 - 908. [Full Text] [PDF]
|
|
|
|
|
|
V. T. Andriole Current and future antifungal therapy: new targets for antifungal agents J. Antimicrob. Chemother., August 1, 1999; 44(2): 151 - 162. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. J. Sheehan, C. A. Hitchcock, and C. M. Sibley Current and Emerging Azole Antifungal Agents Clin. Microbiol. Rev., January 1, 1999; 12(1): 40 - 79. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. L. Fidel Jr., J. A. Vazquez, and J. D. Sobel Candida glabrata: Review of Epidemiology, Pathogenesis, and Clinical Disease with Comparison to C. albicans Clin. Microbiol. Rev., January 1, 1999; 12(1): 80 - 96. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Clarke and I. Chalmers Discussion Sections in Reports of Controlled Trials Published in General Medical Journals: Islands in Search of Continents? JAMA, July 15, 1998; 280(3): 280 - 282. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Fluconazole Prophylaxis in Women AIDS Clinical Care, June 1, 1997; 1997(601): 4 - 4. [Full Text]
|
|
|
|
 |
|
 Fluconazole for Mucosal Candidiasis in HIV Journal Watch Women's Health, June 1, 1997; 1997(601): 12 - 12. [Full Text]
|
|
|
|
 |
|
 FLUCONAZOLE FOR MUCOSAL CANDIDIASIS IN HIV Journal Watch (General), May 6, 1997; 1997(506): 4 - 4. [Full Text]
|
|
|
|
|
|
Fluconazole for Mucosal Candidiasis in HIV Journal Watch Women's Health, May 1, 1997; 1997(501): 15 - 15. [Full Text]
|
|
Article
